HomeAbout usHospitalsSearchLogin
Your medical data, safe and secure.
Name
Dabrafenib
Description
Dabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. FDA approved on May 29, 2013.
No brand information found.
